Table 1 Baseline characteristics of patients
Characteristic | N or mean ± SD |
|---|---|
Sex | |
Male | 8 (33%) |
Female | 16 (67%) |
Age (year) | 66 ± 11 |
Previous systemic therapy | |
Bevacizumab | 14 (58%) |
Cetuximab | 3 (12%) |
Irinotecan | 5 (21%) |
Panitunumab | 1 (4%) |
Tumour burden (% of whole liver) | |
< 10% | 16 (66%) |
> 10% | 8 (34%) |
Metabolic tumour volume (ml) | 99 ± 98 |
90Y-microsphere prescribed activity (MBq) | 1120 ± 503 |
Treatment | |
Whole liver | 6 (25%) |
Lobar | 15 (63%) |
Supra-selective | 3 (12%) |